| Literature DB >> 31483651 |
Orville A Pemberton1, Priyadarshini Jaishankar2, Afroza Akhtar1, Jessie L Adams3, Lindsey N Shaw3, Adam R Renslo2, Yu Chen1.
Abstract
Gram-negative pathogens expressing serine β-lactamases (SBLs) and metallo-β-lactamases (MBLs), especially those with carbapenemase activity, threaten the clinical utility of almost all β-lactam antibiotics. Here we describe the discovery of a heteroaryl phosphonate scaffold that exhibits noncovalent cross-class inhibition of representative carbapenemases, specifically the SBL KPC-2 and the MBLs NDM-1 and VIM-2. The most potent lead, compound 16, exhibited low nM to low μM inhibition of KPC-2, NDM-1, and VIM-2. Compound 16 potentiated imipenem efficacy against resistant clinical and laboratory bacterial strains expressing carbapenemases while showing some cytotoxicity toward human HEK293T cells only at concentrations above 100 μg/mL. Complex structures with KPC-2, NDM-1, and VIM-2 demonstrate how these inhibitors achieve high binding affinity to both enzyme classes. These findings provide a structurally and mechanistically new scaffold for drug discovery targeting multidrug resistant Gram-negative pathogens and more generally highlight the active site features of carbapenemases that can be leveraged for lead discovery.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31483651 PMCID: PMC7175962 DOI: 10.1021/acs.jmedchem.9b00728
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446